Accueil   Diary - News   All news VALBIOTIS announces the First Patient First Visit in the international REVERSE-IT clinical study

VALBIOTIS announces the First Patient First Visit in the international REVERSE-IT clinical study

VALBIOTIS announces the First Patient First Visit in the international Phase II/III REVERSE-IT clinical study on TOTUM-63 to reduce Type 2 Diabetes risk factors

 

First development milestone payment of CHF 3 million from Nestlé Health Science

 

  • The first subject, with fasting hyperglycemia, underwent the initial protocol medical visit prior to randomization at one of the study’s clinical investigation centers.
  • The international REVERSE-IT study will include 600 subjects with altered glucose metabolism, spanning from elevated fasting glycemia to early, yet untreated, Type 2 Diabetes. Its primary endpoint is fasting glycemia and it will be led in more than 30 centers in France and abroad.
  • This First Visit of the First Patient triggers a first milestone payment of CHF 3 million from Nestlé Health Science, thereby strengthening VALBIOTIS’ cash position.

 

La Rochelle, 15 July 2020 (5:40 CEST) VALBIOTIS (FR0013254851 – ALVAL /PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the First Patient First Visit in the international Phase II/III REVERSE-IT clinical study designed to assess TOTUM-63 for the reduction of Type 2 Diabetes metabolic risk factors

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree